

# BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

BBS-Bioactive Bone Substitutes Plc | Company Release | August 19, 2024 at 09:00:00 EEST

## **BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd**

BBS-Bioactive Bone Substitutes Plc ("BBS") has received on August 16, 2024 requests from Riverfort Global Opportunities PCC Ltd ("Riverfort") to convert a proportion of EUR 75,942.20 of the convertible notes into Company shares at a conversion price of EUR 0.27432 per share. The conversion shall be executed by transferring a total of 276,838 treasury shares to Riverfort.

The Conversion price according to the terms and conditions is "90% of the lowest volume weighted average price of a trading day during ten trading days before the applicable subscription notice".

After the transfer, the Company will not hold treasury shares in its possession.

### **For more information, please contact:**

Juliusz Rakowski, CEO

+358 50 448 5132

[juliusz.rakowski@bbs-artebone.fi](mailto:juliusz.rakowski@bbs-artebone.fi)

### **Certified Advisor:**

Nordic Certified Adviser AB,

+46 70 551 67 29,

[info@certifiedadviser.se](mailto:info@certifiedadviser.se)

### **Distribution**

Nasdaq Helsinki

<https://www.bbs-artebone.fi/>

**BBS in brief**

*BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.*

*BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.*

*More information: [www.bbs-artebone.fi](http://www.bbs-artebone.fi)*